Aclaris Therapeutics (STU:8AT) Cyclically Adjusted FCF per Share: €-1.50 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8AT Aclaris Therapeutics Inc STU:8AT
33 GF Score
Price €5.11
GF Value €0.37
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Cyclically Adjusted FCF per Share?

Aclaris Therapeutics STU:8AT +3.21% 33 Cyclically Adjusted FCF per Share is €-1.50 as of Jun. 2026. GuruFocus rates STU:8AT with a GF Score™ of 33/100 and a GF Value™ of €0.37 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aclaris Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.121. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.50 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-18), Aclaris Therapeutics's current stock price is €5.105. Aclaris Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-1.50. Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Aclaris Therapeutics  (STU:8AT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aclaris Therapeutics Cyclically Adjusted FCF per Share Related Terms


Aclaris Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Cyclically Adjusted FCF per Share Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.90 -1.47

Aclaris Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -1.51 -1.47 -1.49 -1.50

STU:8AT vs FTH, AURA, CLYM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:8AT
33GF Score
Aclaris Therapeutics Inc STU:8AT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.121/333.9520*333.9520
=-0.121

Current CPI (Jun. 2026) = 333.9520.

Aclaris Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.415 241.428 -0.574
201612 -0.329 241.432 -0.455
201703 -0.461 243.801 -0.631
201706 -0.344 244.955 -0.469
201709 -0.407 246.819 -0.551
201712 -0.514 246.524 -0.696
201803 -0.582 249.554 -0.779
201806 -0.614 251.989 -0.814
201809 -0.841 252.439 -1.113
201812 -0.620 251.233 -0.824
201903 -0.678 254.202 -0.891
201906 -0.464 256.143 -0.605
201909 -0.531 256.759 -0.691
201912 -0.449 256.974 -0.584
202003 -0.151 258.115 -0.195
202006 -0.228 257.797 -0.295
202009 -0.247 260.280 -0.317
202012 -0.167 260.474 -0.214
202103 -0.204 264.877 -0.257
202106 -0.188 271.696 -0.231
202109 -0.147 274.310 -0.179
202112 -0.247 278.802 -0.296
202203 -0.312 287.504 -0.362
202206 -0.285 296.311 -0.321
202209 -0.121 296.808 -0.136
202212 -0.272 296.797 -0.306
202303 -0.376 301.836 -0.416
202306 -0.273 305.109 -0.299
202309 -0.326 307.789 -0.354
202312 -0.093 306.746 -0.101
202403 -0.271 312.332 -0.290
202406 -0.160 314.175 -0.170
202409 0.278 315.301 0.294
202412 -0.448 315.605 -0.474
202503 -0.105 319.799 -0.110
202506 -0.065 322.561 -0.067
202509 -0.076 324.800 -0.078
202512 -0.092 324.054 -0.095
202603 -0.122 330.213 -0.123
202606 -0.121 333.952 -0.121

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.50 mean?
Aclaris Therapeutics (STU:8AT) has a Cyclically Adjusted FCF per Share of €-1.50 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Cyclically Adjusted FCF per Share too high?
Aclaris Therapeutics' current Cyclically Adjusted FCF per Share is €-1.50. Overall, Aclaris Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Cyclically Adjusted FCF per Share compare to FTH and AURA?
Aclaris Therapeutics' Cyclically Adjusted FCF per Share of €-1.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Cyclically Adjusted FCF per Share is €-1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (STU:8AT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.37, compared to a current price of €5.11 — trading 1279.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.50. Aclaris Therapeutics' overall GF Score™ is 33/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Aclaris Therapeutics (STU:8AT), the current Cyclically Adjusted FCF per Share is €-1.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (STU:8AT) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of €5.11 is trading 1279.7% above its estimated GF Value™ of €0.37. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:8AT:

  • Cyclically Adjusted FCF per Share: €-1.50
  • GF Value™: €0.37 vs. price of €5.11 (1279.7% above fair value)
  • GF Score™: 33/100 with 8 warning signs

No single metric tells the full story. See the STU:8AT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges ACRS:USA0H8T:UK
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for STU:8AT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.11
Price
€0.37
GF Value